Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.10.2011 | Epidemiology

Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age

verfasst von: Hala H. Nsouli-Maktabi, Donald E. Henson, Naji Younes, Heather A. Young, Sean D. Cleary

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer incidence increases with age and exhibits a Black-to-White crossover around age 45. Breast cancer survivors are at a significantly elevated risk of developing a second primary breast or gynecological cancer compared with the general population. The purpose of this study was to determine whether a similar crossover occurs in hormonally related second primary breast, endometrial, or ovarian cancers in Black and White women. The Surveillance, Epidemiology, and End Results’ Registry 9 was used to follow 415,664 White and 39,887 Black female breast cancer survivors, diagnosed at age 19 or older, for a second primary breast, endometrial, or ovarian cancer between 1973 and 2007. Cumulative incidence curves were generated; Pepe and Mori’s test was used to test for significance. Second primary breast cancer followed the incidence pattern of the first primary breast cancer in Black and White women diagnosed before age 45. It was opposite of the pattern of first primary breast cancer in Black and White women diagnosed at age 45 or later. Second primary endometrial and ovarian cancers paralleled the incidence pattern of first primaries of the same anatomic site among Black and White women, independent of the age at diagnosis of the first primary breast cancer. Despite the Black-to-White crossover of first primary breast cancer around age 40, the incidence of hormonally related second primaries does not appear affected by the age at diagnosis of the first primary.
Literatur
1.
Zurück zum Zitat Rice LW (2010) Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol 118(2):202–207PubMedCrossRef Rice LW (2010) Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol 118(2):202–207PubMedCrossRef
2.
Zurück zum Zitat Cortesi L, De Matteis E, Rashid I, Cirilli C, Proietto M, Rivasi F, Federico M (2009) Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer 19(8):1358–1363PubMedCrossRef Cortesi L, De Matteis E, Rashid I, Cirilli C, Proietto M, Rivasi F, Federico M (2009) Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer 19(8):1358–1363PubMedCrossRef
3.
4.
Zurück zum Zitat Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie E, Olivotto IA (2007) Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 110(1):31–37PubMedCrossRef Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie E, Olivotto IA (2007) Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 110(1):31–37PubMedCrossRef
5.
Zurück zum Zitat Ursic Vrscaj M, Kovacic J, Bebar S, Djurisic A, Fras PA, Robic V (2001) Endometrial and other primary cancers after tamoxifen treatment of breast cancer—results of retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 95(1):105–110PubMedCrossRef Ursic Vrscaj M, Kovacic J, Bebar S, Djurisic A, Fras PA, Robic V (2001) Endometrial and other primary cancers after tamoxifen treatment of breast cancer—results of retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 95(1):105–110PubMedCrossRef
6.
Zurück zum Zitat Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113(5):1027–1037PubMed Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113(5):1027–1037PubMed
7.
Zurück zum Zitat (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London. Lancet 341(8856):1293–1298 (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London. Lancet 341(8856):1293–1298
8.
Zurück zum Zitat (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 348(9036):1189–1196 (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 348(9036):1189–1196
9.
Zurück zum Zitat Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100(24):1804–1814PubMedCrossRef Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100(24):1804–1814PubMedCrossRef
10.
Zurück zum Zitat Fong M, Henson DE, Devesa SS, Anderson WF (2006) Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. Breast Cancer Res Treat 97(1):57–65PubMedCrossRef Fong M, Henson DE, Devesa SS, Anderson WF (2006) Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. Breast Cancer Res Treat 97(1):57–65PubMedCrossRef
11.
Zurück zum Zitat Karami S, Young HA, Henson DE (2007) Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev 31(1):29–34PubMedCrossRef Karami S, Young HA, Henson DE (2007) Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev 31(1):29–34PubMedCrossRef
12.
Zurück zum Zitat Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005–2006) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23 Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005–2006) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23
13.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975PubMedCrossRef Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975PubMedCrossRef
14.
Zurück zum Zitat Kovi J, Mohla S, Norris HJ, Sampson CC, Heshmat MY (1989) Breast lesions in black women. Pathol Annu 24(Pt 1):199–218PubMed Kovi J, Mohla S, Norris HJ, Sampson CC, Heshmat MY (1989) Breast lesions in black women. Pathol Annu 24(Pt 1):199–218PubMed
15.
Zurück zum Zitat Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds) (2008) SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds) (2008) SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2005/​, based on November 2007 SEER data submission, posted to the SEER web site
16.
Zurück zum Zitat Hunter MI, Ziogas A, Flores F, Brewster WR (2007) Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer. Am J Clin Oncol 30(1):1–7PubMedCrossRef Hunter MI, Ziogas A, Flores F, Brewster WR (2007) Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer. Am J Clin Oncol 30(1):1–7PubMedCrossRef
17.
Zurück zum Zitat Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM (2009) Ovarian cancer risk factors in African–American and white women. Am J Epidemiol 170(5):598–606PubMedCrossRef Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM (2009) Ovarian cancer risk factors in African–American and white women. Am J Epidemiol 170(5):598–606PubMedCrossRef
18.
Zurück zum Zitat Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16(1):53–56PubMed Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16(1):53–56PubMed
19.
Zurück zum Zitat Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, Schouten LJ (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189PubMedCrossRef Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, Schouten LJ (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189PubMedCrossRef
22.
Zurück zum Zitat Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706 ReviewPubMedCrossRef Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706 ReviewPubMedCrossRef
23.
Zurück zum Zitat Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(7):1229–1235PubMedCrossRef Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(7):1229–1235PubMedCrossRef
24.
Zurück zum Zitat Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef
25.
Zurück zum Zitat Rubino C, Arriagada R, Delaloge S, Lê MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102(1):213–219PubMedCrossRef Rubino C, Arriagada R, Delaloge S, Lê MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102(1):213–219PubMedCrossRef
26.
Zurück zum Zitat Nasseri K (2004) Secular trends in the incidence of female breast cancer in the United States, 1973–1998. Breast J 10(2):129–135PubMedCrossRef Nasseri K (2004) Secular trends in the incidence of female breast cancer in the United States, 1973–1998. Breast J 10(2):129–135PubMedCrossRef
27.
Zurück zum Zitat Bower JK, Schreiner PJ, Sternfeld B, Lewis CE (2009) Black–White differences in hysterectomy prevalence: the CARDIA study. Am J Public Health 99(2):300–307PubMedCrossRef Bower JK, Schreiner PJ, Sternfeld B, Lewis CE (2009) Black–White differences in hysterectomy prevalence: the CARDIA study. Am J Public Health 99(2):300–307PubMedCrossRef
28.
Zurück zum Zitat Sherman ME, Carreon JD, Lacey JV Jr, Devesa SS (2005) Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 97(22):1700–1702PubMedCrossRef Sherman ME, Carreon JD, Lacey JV Jr, Devesa SS (2005) Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 97(22):1700–1702PubMedCrossRef
29.
Zurück zum Zitat Weiss G, Noorhasan D, Schott LL, Powell L, Randolph JF Jr, Johnston JM (2009) Racial differences in women who have a hysterectomy for benign conditions. Womens Health Issues 19(3):202–210PubMedCrossRef Weiss G, Noorhasan D, Schott LL, Powell L, Randolph JF Jr, Johnston JM (2009) Racial differences in women who have a hysterectomy for benign conditions. Womens Health Issues 19(3):202–210PubMedCrossRef
30.
Zurück zum Zitat Banerjee M, George J, Yee C, Hryniuk W, Schwartz K (2007) Disentangling the effects of race on breast cancer treatment. Cancer 110(10):2169–2177PubMedCrossRef Banerjee M, George J, Yee C, Hryniuk W, Schwartz K (2007) Disentangling the effects of race on breast cancer treatment. Cancer 110(10):2169–2177PubMedCrossRef
31.
Zurück zum Zitat Schwartz AG, Ragheb NE, Swanson GM, Satariano WA (1989) Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 14(2):245–254PubMedCrossRef Schwartz AG, Ragheb NE, Swanson GM, Satariano WA (1989) Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 14(2):245–254PubMedCrossRef
32.
Zurück zum Zitat Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308PubMedCrossRef Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308PubMedCrossRef
33.
Zurück zum Zitat Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG (1992) Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 84(11):872–877PubMedCrossRef Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG (1992) Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 84(11):872–877PubMedCrossRef
34.
Zurück zum Zitat Merrill RM, Dearden KA (2004) How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 15(10):1027–1034PubMedCrossRef Merrill RM, Dearden KA (2004) How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 15(10):1027–1034PubMedCrossRef
35.
Zurück zum Zitat Gomez SL, Glaser SL (2006) Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control 17(6):771–781PubMedCrossRef Gomez SL, Glaser SL (2006) Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control 17(6):771–781PubMedCrossRef
36.
Zurück zum Zitat Patel DA, Knowles A, Schwartz AG, Schwartz K (2005) Evaluation of African–American and white racial classification in a surveillance, epidemiology, and end results cancer registry. Ethn Dis 15(4):713–719PubMed Patel DA, Knowles A, Schwartz AG, Schwartz K (2005) Evaluation of African–American and white racial classification in a surveillance, epidemiology, and end results cancer registry. Ethn Dis 15(4):713–719PubMed
Metadaten
Titel
Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age
verfasst von
Hala H. Nsouli-Maktabi
Donald E. Henson
Naji Younes
Heather A. Young
Sean D. Cleary
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1560-9

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.